GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Syneos Health Inc (NAS:SYNH) » Definitions » Peter Lynch Fair Value

Syneos Health (Syneos Health) Peter Lynch Fair Value : $23.25 (As of Apr. 25, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Syneos Health Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Here, as of today, Syneos Health's PEG is 1. Syneos Health's 5-Year TTM EBITDA Growth Rate is 10.46. Syneos Health's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 was $2.22. Therefore, the Peter Lynch Fair Value for today is $23.25.

As of today (2024-04-25), Syneos Health's share price is $42.98. Syneos Health's Peter Lynch fair value is $23.25. Therefore, Syneos Health's Price to Peter Lynch Fair Value Ratio for today is 1.85.


The historical rank and industry rank for Syneos Health's Peter Lynch Fair Value or its related term are showing as below:

SYNH' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.56   Med: 2.74   Max: 20.29
Current: 1.85


During the past 12 years, the highest Price to Peter Lynch Fair Value Ratio of Syneos Health was 20.29. The lowest was 0.56. And the median was 2.74.


SYNH's Price-to-Peter-Lynch-Fair-Value is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 1.62 vs SYNH: 1.85

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Syneos Health Peter Lynch Fair Value Historical Data

The historical data trend for Syneos Health's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syneos Health Peter Lynch Fair Value Chart

Syneos Health Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Peter Lynch Fair Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.52 26.50 24.10 60.23 79.06

Syneos Health Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 90.00 89.83 79.06 52.85 23.25

Competitive Comparison of Syneos Health's Peter Lynch Fair Value

For the Diagnostics & Research subindustry, Syneos Health's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syneos Health's Price-to-Peter-Lynch-Fair-Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Syneos Health's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Syneos Health's Price-to-Peter-Lynch-Fair-Value falls into.



Syneos Health Peter Lynch Fair Value Calculation

Syneos Health's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* 10.46 *2.223
=23.25

Syneos Health's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.22.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Syneos Health  (NAS:SYNH) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 10.46 instead of 15 in this case.

Syneos Health's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=42.98/23.25
=1.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Syneos Health Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Syneos Health's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Syneos Health (Syneos Health) Business Description

Traded in Other Exchanges
N/A
Address
1030 Sync Street, Morrisville, NC, USA, 27560-5468
Syneos is a global contract research and outsourced commercialization organization that provides services to pharmaceutical and biotechnology firms. Its clinical solutions segment offers early- to late-stage clinical trial support that ranges from specialized staffing models to strategic partnerships that oversee nearly all aspects of a drug program, while the company's commercialization solutions includes outsourced sales, consulting, public relations, and advertising services.
Executives
Michael J. Bonello officer: Chief Financial Officer 4130 PARKLAKE AVENUE, SUITE 400, RALEIGH NY 27612
Stanford Rudnick officer: See remarks C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560-5468
Christian Tucat officer: Chief Business Officer C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560-5468
Michael Lee Brooks officer: See remarks C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Jonathan Olefson officer: General Counsel & Corp Secty C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Michelle Keefe officer: Pres., Commercial Solutions C/O SYNEOS HEALTH,INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Jason M. Meggs officer: Chief Financial Officer C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Donna Hildebrand Kralowetz officer: SVP, Chief Accounting Officer C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Matthew E. Monaghan director ONE INVACARE WAY, ELYRIA OH 44035
Alfonso G Zulueta director 4925 INDIANA AVE, LISLE IL 60532
Barbara W. Bodem director C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Linda S Harty director MEDTRONIC PLC, 710 MEDTRONIC PARKWAY NE, LC-150, MINNEAPOLIS MN 55432
Alistair Macdonald officer: Chief Operating Officer C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
David S. Wilkes director ONE BAXTER PARKWAY, DEERFIELD IL 60015
Advent International Corp/ma 10 percent owner 800 BOYLSTON STREET SUITE 3300, BOSTON MA 02199

Syneos Health (Syneos Health) Headlines

From GuruFocus